Healthcare
Teleflex Incorporated(TFX)
Live Price
Offline$127.00
+1.63% today
1Y Change
+7.57%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $5.39B
- Revenue Growth
- -34.6%
- EPS Growth
- -1462.4%
- Dividend Yield
- 1.1%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Teleflex Incorporated (TFX) is a Healthcare stock with a market cap of $5.39B and listed on NYSE. The stock last traded around $127.00 and up 7.6% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -34.6%, EPS growth of -1462.4%, a dividend yield of 1.1%. What stands out right now is revenue -34.6%, EPS -1462.4%, free cash flow -51.8% with operating margin 9.7% and ROIC 4.3%. The dividend is present but secondary, with a yield around 1.1%. Valuation is more restrained than many high-expectation growth names at price/sales 1.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TFX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-34.6% vs +7.6% peer median
Operating Margin
Below sector median
+9.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -34.6% and EPS is at -1462.4%, with operating margin around 9.7%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.1%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +1.0% | -1.1% | -1.4% |
2026 Feb 26, 2026 | -48.3% | +2.6% | -1.2% | -7.2% |
2025 Nov 6, 2025 | +8.6% | +0.8% | +0.9% | +11.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TFX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TFX Max Drawdown
-24.59%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TFX and SPY.
Company Overview
Teleflex Incorporated
New York Stock Exchange
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
- Leadership
- Stuart A. Randle
- IPO Date
- Mar 17, 1980
- Employees
- 14.1k
- Street Address
- 550 East Swedesford Road
- Mailing
- Wayne, PA, 19087-1603
- Region
- Wayne, PA, US
- Reporting Currency
- USD
- Investor Line
- 610 225 6800
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 70.1
- Price/Sales
- 1.8
- Price/Book
- 1.7
Growth
- Revenue
- -34.6%
- EPS
- -1462.4%
- Free Cash Flow
- -51.8%
Profitability
- Gross Margin
- 53.3%
- Operating Margin
- 9.7%
- Net Margin
- -30.6%
- ROE
- -23.7%
- ROIC
- 4.3%
Balance Sheet
- Debt/Equity
- 0.87
- Current Ratio
- 2.54
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.